In addition to providing attendees with the opportunity to earn more than 12 hours of continuing pharmacy education credits, the Pharmacy Track at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® will offer 4 hours of board-certified oncology pharmacist (BCOP) credit in collaboration with the Hematology/Oncology Pharmacy Association (HOPA) over 2 days.

“A lot of the pharmacist attendees do require special certification, so a few years ago we added this special certification credit because it can be difficult to get those credits at other venues,” said Pharmacy Track Chair Nicole Daukshus, PharmD, BCOP, pediatric hematology/oncology clinical pharmacy specialist II at Memorial Sloan Kettering Cancer Center.

While pharmacists are the primary target for this programming, Daukshus said many of the topics being presented relate to immunotherapy, gene therapy, and transplant-specific complications, and are of interest to advanced practice providers, fellows, and newer physicians, as well as others. The track faculty mirror this diverse appeal.

“We have a broad range of speakers,” Daukshus said. “We have plenty of pharmacists, but we have a good mix of physicians and pharmacists leading most of the sessions for the Pharmacy Track this year.”

Among the BCOP topics is the management of refractory chimeric antigen receptor (CAR) T-cell therapy side effects, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). On Feb. 14, The Wild West: Navigating Refractory CRS and ICANS will begin at 11 a.m.

A debate on gene therapy versus transplant for sickle cell disease and a session on acute graft-versus-host disease (GVHD) updates, both on Feb. 15, also are eligible for BCOP credit. Gene Therapy vs. Hematopoietic Cell Transplantation in Sickle Cell Disease will begin at 11 a.m. and Acutely Aware of the Advancements Needed in Acute GVHD Management will begin at 1:45 p.m.

Another BCOP-eligible session will continue a collaboration that began last year to explore bridging chemotherapy prior to CAR-T therapy with speakers from the United States and the United Kingdom. CAR T & Bridging Chemotherapy will begin at 2 p.m. on Feb. 14.

“Europe does things differently management-wise compared to what we’re doing in the United States, so it’s good to hear their perspective,” Daukshus said. “And we had great feedback from the session last year, which is why we’re continuing it this year and planning to continue it for the future.”

Other hot topics in the Pharmacy Track include artificial intelligence, pharmacokinetics, respiratory syncytial virus, and aplastic anemia. On Feb. 14, ChatBMT: Harnessing AI to Elevate Your Clinical Practice  will begin at 8:15 a.m. and Pharmacokinetics and Pharmacodynamics of Fludarabine, Melphalan and Anti-thymocyte Globulin in Stem Cell Transplant will begin at 3:30 p.m. On Feb. 15, Respiratory Syncytial Virus in HCT and CAR-T Therapy Patients will begin at 10:30 a.m. and Acquired Aplastic Anemia: Current Approaches, Predictive Biomarkers and Future Directions will begin at 1 p.m.

The program will also include several returning sessions, including the Pharmacy SIG Update at 8:45 a.m. on Feb. 14 and the Best Practice Panel focusing on outpatient CAR T-cell and bispecific T-cell engager administration. The Ins and Out(patients) of Cellular Therapy: Comparative Insights, Safety Strategies, and the Pharmacist’s Role in Cellular Therapy Success will begin at 8:15 a.m. on Feb. 15.

The mentorship program of the Pharmacy Special Interest Group will be highlighted in two sessions: ASH Updates Part 1 at 9:15 a.m. on Feb. 14 and A Guide to Mindful Mobilization – Optimizing Stem Cell Collection in Autologous Transplantation at 9:30 a.m. on Feb. 15. A mentor with experience presenting at national conferences is paired with a mentee who is a first-time presenter.

“If you’ve never presented at a conference, it could be pretty daunting,” Daukshus said. “A lot of our newer clinicians, they’re happy to present, and to have someone lead them along the way helps take the scariness out of the presentation.”

Outside of the sessions, Daukshus recommends attendees make time for the Pharmacy Track Reception and Awards Presentation at 5:30 p.m. on Feb. 14 and other networking opportunities throughout the Tandem Meetings.

Pharmacy Track Agenda

The most up-to-date Pharmacy Track agenda and the full 2025 Tandem Meetings program are available on the online meeting platform. All Pharmacy Track sessions take place in Room 311 of the Hawaiʻi Convention Center, unless noted otherwise. Formal sessions will be available for on-demand viewing for registered attendees following the live presentations.

Friday, Feb. 14

• 8-8:15 a.m. – Welcome/Overview 2025 Pharmacy Conference
• 8:15-8:45 a.m. – ChatBMT: Harnessing AI to Elevate Your Clinical Practice
• 8:45-9:15 a.m. – Pharmacy SIG Update
• 9:15-10 a.m. – ASH Updates Part 1
• 10-10:15 a.m. – Morning Break, Exhibit Hall 2
• 10:15-11 a.m. – ASH Updates Part 2
• 11 a.m.-noon – The Wild West: Navigating Refractory CRS and ICANS
• Noon-1 p.m. – Lunch, Exhibit Hall 2
• 1-2 p.m. – Sequencing of Therapy and Role of HCT in Multiple Myeloma
• 2-3 p.m. – CAR T & Bridging Chemotherapy
• 3-3:30 p.m. – Afternoon Break, Level 3 Concourse
• 3:30-4 p.m. – Pharmacokinetics and Pharmacodynamics of Fludarabine, Melphalan and Anti-thymocyte Globulin in Stem Cell Transplant
• 4-4:15 p.m. – Afternoon Break, Level 3 Concourse
• 4:15-5:30 – NIA Grant Winner and Best Abstracts
• 6:30-8 p.m. – Pharmacy Track Reception and Awards Presentation

Saturday, Feb. 15

• 8-8:15 a.m. – Welcome Session Day 2
• 8:15-9:30 a.m. – The Ins and Out(patients) of Cellular Therapy: Comparative Insights, Safety Strategies, and the Pharmacist’s Role in Cellular Therapy Success
• 9:30-10 a.m. – A Guide to Mindful Mobilization – Optimizing Stem Cell Collection in Autologous Transplantation
• 10-10:30 a.m. – Morning Break, Exhibit Hall 2
• 10:30-11 a.m. – Respiratory Syncytial Virus in HCT and CAR-T Therapy Patients
• 11 a.m.-noon – Gene Therapy vs. Hematopoietic Cell Transplantation in Sickle Cell Disease
• Noon-1 p.m. – Lunch, Exhibit Hall 2
• 1-1:45 p.m. – Acquired Aplastic Anemia: Current Approaches, Predictive Biomarkers and Future Directions
• 1:45-2:45 p.m. – Acutely Aware of the Advancements Needed in Acute GVHD Management
• 2:45-3:15 p.m – New Directions in Therapies for Pediatric Leukodystrophies
• 3:15-3:45 p.m. – Afternoon Break, Level 3 Concourse
• 3:45-4:15 p.m. – Raising the Epstein-Barr: A Challenging Case of Refractory EBV PTLD